研報掘金丨國投證券:維持中金公司“買入-A”評級,目標價38.71元
國投證券研報指出,中金公司(601995.SH)24年全年實現營業收入213億元(YoY-7.21%),歸母淨利潤57億元(YoY-7.50%),股票業務營收滑落,固收利潤率大幅提升。公司債券承銷和交易量持續保持市場領先地位,中資外幣債券排名全市場第一。截至2024年末,公司財富管理產品規模連續五年正增長,增長至近3700億元,不斷豐富完善50系列買方投顧體系。展望後續,打造一流投行、行業競爭加劇背景下,公司作爲頭部券商有望受益。給予1.55x2025年P/B,對應6個月目標價38.71元,維持“買入-A”投資評級。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.